Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CAR T-Cell Therapy”

1,420 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,420 results

Not applicableUnknownNCT04916860
What this trial is testing

Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Who this might be right for
SenL-T7 CAR T Cells for CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Hebei Senlang Biotechnology Inc., Ltd. 100
Early research (Phase 1)Not Yet RecruitingNCT06633042
What this trial is testing

The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD

Who this might be right for
Autoimmune Disease
Bioray Laboratories 18
Not applicableLooking for participantsNCT07234110
What this trial is testing

CD5 CART for the Treatment of Relapsed and Refractory CD5 Hematological Tumors

Who this might be right for
Relapsed and Refractory CD5 Hematological Tumors
Institute of Hematology & Blood Diseases Hospital, China 18
Testing effectiveness (Phase 2)UnknownNCT04935580
What this trial is testing

Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients

Who this might be right for
Multiple Myeloma
Shanghai Changzheng Hospital 20
Early research (Phase 1)Looking for participantsNCT05741359
What this trial is testing

The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma

Who this might be right for
Non-hodgkin Lymphoma,B Cell
Bioray Laboratories 18
Early research (Phase 1)Looking for participantsNCT07239323
What this trial is testing

In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies

Who this might be right for
B-Acute Lymphoblastic LeukemiaB Cell Non-Hodgkin's LymphomaMultiple Myeloma
Chongqing Precision Biotech Co., Ltd 24
Testing effectiveness (Phase 2)Study completedNCT03097770
What this trial is testing

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20

Who this might be right for
Hematopoietic/Lymphoid CancerAdult Acute Lymphoblastic Leukemia in RemissionB-cell Adult Acute Lymphoblastic Leukemia+20 more
Chinese PLA General Hospital 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT07493395
What this trial is testing

Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy

Who this might be right for
Scleroderma, Systemic
University Hospital, Montpellier 6
Early research (Phase 1)Study completedNCT03602612
What this trial is testing

T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma

Who this might be right for
Myeloma-MultipleMyeloma, Plasma-Cell
National Cancer Institute (NCI) 35
Very early researchWithdrawnNCT07410377
What this trial is testing

UCAR T-cell Therapy Targeting CD19/ BCMA(QT-019C) in Patients With Relapse/ Refractory Autoimmune Diseases

Who this might be right for
Systemic Lupus ErythematosusInflammatory Myopathy
The Affiliated Hospital of Xuzhou Medical University
Early research (Phase 1)Looking for participantsNCT06010875
What this trial is testing

A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Who this might be right for
Renal Cell CarcinomaOvarian CancerCervix Cancer+2 more
Chongqing Precision Biotech Co., Ltd 48
Testing effectiveness (Phase 2)Active Not RecruitingNCT03573700
What this trial is testing

Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia

Who this might be right for
Acute Lymphoblastic Leukemia, in RelapseAcute Lymphoblastic Leukemia, Refractory
St. Jude Children's Research Hospital 24
Not applicableNot Yet RecruitingNCT06993766
What this trial is testing

The Predictability of CD19 Expression Across Primitive Cellular Fractions of Relapsed B-ALL on Outcomes of CD19-targeted CAR T-cells

Who this might be right for
Relapsed B-ALLCAR T-cellsCD19-directed CAR T-cell Therapy
King Faisal Specialist Hospital & Research Center 100
Not applicableStudy completedNCT05349201
What this trial is testing

CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)

Who this might be right for
Diffuse Large B-Cell Lymphoma (DLBCL)Acute Lymphoblastic Leukemia (ALL)
Novartis Pharmaceuticals 273
Not applicableUnknownNCT04237428
What this trial is testing

CD19-CART in the Treatment of R/R CD19 Positive Non-Hodgkin's Lymphoma

Who this might be right for
Non Hodgkin Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 20
Not applicableLooking for participantsNCT07472972
What this trial is testing

Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0)

Who this might be right for
LymphomaLymphoid Hematological Malignancies
University of Zurich 50
Early research (Phase 1)Looking for participantsNCT07361094
What this trial is testing

Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases

Who this might be right for
Relapsed/Refractory Systemic Lupus ErythematosusRelapsed/Refractory Systemic SclerosisRelapsed/Refractory Idiopathic Inflammatory Myopathies+3 more
Beijing Boren Hospital 12
Testing effectiveness (Phase 2)Looking for participantsNCT05464719
What this trial is testing

A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy

Who this might be right for
Large B-cell LymphomaLymphoma
M.D. Anderson Cancer Center 30
Testing effectiveness (Phase 2)Ended earlyNCT05938725
What this trial is testing

KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

Who this might be right for
Lupus NephritisLupus Nephritis - World Health Organization (WHO) Class IIILupus Nephritis - WHO Class IV
Kyverna Therapeutics 6
Testing effectiveness (Phase 2)Looking for participantsNCT06911710
What this trial is testing

The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors

Who this might be right for
Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL)AML (Acute Myelogenous Leukemia)Myeloma Multiple+3 more
Tianjin Medical University General Hospital 90
Next Page